SEARCH

SEARCH BY CITATION

References

  • 1
    Jaffe ES, Ralfkiaer E. Mature T-cell and NK-cell neoplasms: introduction. In World health organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, JaffeES, HarrisNL, SteinH, VardimanJW (eds). IARC Press: Lyon, 2001; 191194.
  • 2
    The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89(11): 39093918.
  • 3
    Armitage JO, Vose JM, Weisenburger DD. Towards understanding the peripheral T-cell lymphomas. Ann Oncol 2004; 15(10): 14471449.
  • 4
    Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13(1): 140149.
  • 5
    Vose JM. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood 2005; 1006(11): 239 (abs. #811).
  • 6
    Levine PH, Blattner WA, Clark J, et al. Geographic distribution of HTLV-I and identification of a new high-risk population. Int J Cancer 1988; 42(1): 7712.
  • 7
    Kondo T, Kono H, Nonaka H, et al. Risk of adult T-cell leukaemia/lymphoma in HTLV-I carriers. Lancet 1987; 2(8551): 159.
  • 8
    Vidal AU, Gessain A, Yoshida M, et al. Molecular epidemiology of HTLV type I in Japan: evidence for two distinct ancestral lineages with a particular geographical distribution. AIDS Res Hum Retroviruses 1994; 10(11): 15571566.
  • 9
    Hirose Y, Masaki Y, Sawaki T, et al. Association of Epstein-Barr virus with human immunodeficiency virus-negative peripheral T-cell lymphomas in Japan. Eur J Haematol 2006; 76(2): 109118.
  • 10
    Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 1992; 80(7): 18041812.
  • 11
    de Bruin PC, Jiwa M, Oudejans JJ, et al. Presence of Epstein-Barr virus in extranodal T-cell lymphomas: differences in relation to site. Blood 1994; 83(6): 16121618.
  • 12
    Geissinger E, Bonzheim I, Krenacs L, et al. Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations. J Pathol 2006; 210(2): 172180.
  • 13
    Rudiger T, Geissinger E, Muller-Hermelink HK. ‘Normal counterparts’ of nodal peripheral T-cell lymphoma. Hematol Oncol 2006; 24(4): 175180.
  • 14
    Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med 2000; 343(2): 108117.
  • 15
    Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000; 343(1): 3749.
  • 16
    Armitage JO, Liang RHS, Sweetenham JW, Reyes F, Jaffe ES, Raffeld M. Mature nodal and extranodal T-cell and Non-Hodgkin-cell lymphomas (peripheral T-cell, angioimmunoblastic, nasal natural killer/T-cell, hepatosplenic T-cell, enteropathy-type T-cell, and subcutaneous panniculitis-like T-cell lymphomas). In Non-Hodgkin's Lymphomas, MauchPM, ArmitageJ, CoiffierB, Dalla-FaveraR, HarrisNL (eds). Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2004; 405426.
  • 17
    Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006; 18(3): 349356.
  • 18
    Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T-cells. Nature 2006; 441(7090): 235238.
  • 19
    Bluestone JA, Tang Q. How do CD4+ CD25+ regulatory T-cells control autoimmunity? Curr Opin Immunol 2005; 17(6): 638642.
  • 20
    Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T-cells express CXC chemokine receptor 5, localize to B-cell follicles, and support immunoglobulin production. J Exp Med 2000; 192(11): 15451552.
  • 21
    Estes JD, Thacker TC, Hampton DL, et al. Follicular dendritic cell regulation of CXCR4-mediated germinal center CD4 T-cell migration. J Immunol 2004; 173(10): 61696178.
  • 22
    Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T-cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5(11): 853865.
  • 23
    Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, Butcher EC. Unique gene expression program of human germinal center T helper cells. Blood 2004; 104(7): 19521960.
  • 24
    Berger CL, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005; 105(4): 16401647.
  • 25
    Wolke C, Tadje J, Bukowska A, et al. Assigning the phenotype of a natural regulatory T-cell to the human T-cell line, KARPAS-299. Int J Mol Med 2006; 17(2): 275278.
  • 26
    Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T-cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004; 126(1): 8184.
  • 27
    Kohno T, Yamada Y, Akamatsu N, et al. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T-cells. Cancer Sci 2005; 96(8): 527533.
  • 28
    Grogg KL, Attygale AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol 2006; 19(8): 11011107.
  • 29
    Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T-cells. Am J Surg Pathol 2006; 30(4): 490494.
  • 30
    Tsuchiya T, Ohshima K, Karube K, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 2004; 103(1): 236241.
  • 31
    Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004; 10(16): 54945500.
  • 32
    Jones D, O'Hara C, Kraus MD, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 2000; 96(2): 685690.
  • 33
    Kiyokawa T, Yamaguchi K, Takeya M, et al. Hypercalcemia and osteoclast proliferation in adult T-cell leukemia. Cancer 1987; 59(6): 11871191.
  • 34
    Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T-cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 1997; 100(8): 19691979.
  • 35
    Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87(4): 12071210.
  • 36
    Jaffe ES, Krenacs L, Kumar S, Kingma DW, Raffeld M. Extranodal peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol 1999; 111 (Suppl. 1): S46S55.
  • 37
    Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96(12): 36813695.
  • 38
    Schlegelberger B, Himmler A, Bartles H, Kuse R, Sterry W, Grote W. Recurrent chromosome abnormalities in peripheral T-cell lymphomas. Cancer Genet Cytogenet 1994; 78(1): 1522.
  • 39
    Schlegelberger B, Himmler A, Godde E, Grote W, Feller AC, Lennert K. Cytogenetic findings in peripheral T-cell lymphomas as a basis for distinguishing low-grade and high-grade lymphomas. Blood 1994; 83(2): 505511.
  • 40
    Lepretre S, Buchonnet G, Stamatoullas A, et al. Chromosome abnormalities in peripheral T-cell lymphoma. Cancer Genet Cytogenet 2000; 117(1): 7179.
  • 41
    Chen CY, Yao M, Tang JL, et al. Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan: with special reference to T-cell lymphoma. Ann Oncol 2004; 15(7): 10911096.
  • 42
    Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004; 164(5): 18371848.
  • 43
    Martinez-Delgado B. Peripheral T-cell lymphoma gene expression profiles. Hematol Oncol 2006; 24(3): 113119.
  • 44
    Martinez-Delgado B, Melendez B, Cuadros M, et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res 2004; 10(15): 49714982.
  • 45
    Martinez-Delgado B, Cuadros M, Honrado E, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005; 19(12): 22542263.
  • 46
    Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006; 25(10): 15601570.
  • 47
    Piccaluga PP, Agostinelli C, Zupo S, et al. Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals the existance of two subgroups related to different-cellular counterparts. Ann Oncol 2005; 16(Suppl. 5): v74 (abs. #125).
  • 48
    Ralfkiaer E, Müller-Hermelink HK, Jaffe ES. Peripheral T-cell lymphoma, unspecified. In World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, JaffeES, HarrisNL, SteinH, VardimanJW (eds). IARC Press: Lyon, 2001; 227229.
  • 49
    Suchi T, Lennert K, Tu LY, et al. Histopathology and immunohistochemistry of peripheral T-cell lymphomas: a proposal for their classification. J Clin Pathol 1987; 40(9): 9951015.
  • 50
    Patsouris E, Noel H, Lennert K. Histological and immunohistological findings in lymphoepithelioid cell lymphoma (Lennert's lymphoma). Am J Surg Pathol 1988; 12(5): 341350.
  • 51
    Lennert K, Feller AC. Histopathology of Non-Hodgkin's Lymphomas (based on the Updated Kiel classification). Springer– Verlag: Berlin, 1992.
  • 52
    Weiss LM, Crabtree GS, Rouse RV, Warnke RA. Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas. Am J Pathol 1985; 118(2): 316324.
  • 53
    Borowitz MJ, Reichert TA, Brynes RK, et al. The phenotypic diversity of peripheral T-cell lymphomas: the Southeastern Cancer Study Group experience. Hum Pathol 1986; 17(6): 567574.
  • 54
    Peripheral T-cell Lymphoma. In Text atlas of lymphomas (revised edition), ArmitageJO, CavalliF, ZuccaE, LongoDL (eds). Martin Dunitz: London, 2002; 3043.
  • 55
    Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ann Oncol 1997; 8(6): 583592.
  • 56
    Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification. Ann Oncol 1998; 9(8): 849855.
  • 57
    Arrowsmith ER, Macon WR, Kinney MC, et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma 2003; 44(2): 241249.
  • 58
    Kojima H, Hasegawa Y, Suzukawa K, et al. Clinicopathological features and prognostic factors of Japanese patients with “peripheral T-cell lymphoma, unspecified” diagnosed according to the WHO classification. Leuk Res 2004; 28(12): 12871292.
  • 59
    Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15(10): 14671475.
  • 60
    Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103(7): 24742479.
  • 61
    Reimer P, Schertlin T, Rudiger T, et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 2004; 5(4): 304311.
  • 62
    Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92(1): 7682.
  • 63
    Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1990; 1(1): 4550.
  • 64
    Ansell SM, Habermann TM, Kurtin PJ, et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997; 15(6): 22962301.
  • 65
    Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89(12): 45144520.
  • 66
    Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-airlie house, Virginia, November 1997. J Clin Oncol 1999; 17(12): 38353849.
  • 67
    Harris NL, Jaffe ES, Stein H, et al. A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84(5): 13611392.
  • 68
    Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93(8): 26972706.
  • 69
    Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93(11): 39133921.
  • 70
    Lippman SM, Miller TP, Spier CM, Slymen DJ, Grogan TM. The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. Blood 1988; 72(2): 436441.
  • 71
    Cheng AL, Chen YC, Wang CH, et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades—should peripheral T-cell lymphoma be considered separately? J Clin Oncol 1989; 7(6): 725731.
  • 72
    Kwak LW, Wilson M, Weiss LM, et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. J Clin Oncol 1991; 9(8): 14261431.
  • 73
    Armitage JO, Greer JP, Levine AM, et al. Peripheral T-cell lymphoma. Cancer 1989; 63(1): 158163.
  • 74
    Sonnen R, Schmidt WP, Muller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005; 129(3): 366372.
  • 75
    d'Amore F, Johansen P, Houmand A, Weisenburger DD, Mortensen LS. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO. Blood 1996; 87(3): 10451055.
  • 76
    Dupuis J, Emile JF, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006; 108(13): 41634169.
  • 77
    Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006; 24(16): 24722479.
  • 78
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328(14): 10021006.
  • 79
    Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54(1): 182190.
  • 80
    You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004; 15(4): 618625.
  • 81
    Cheung MM, Chan JK, Wong KH, Ngan RK, Lau WH. Early stage nasal NK/T-cell lymphoma: preliminary result of intensifying treatment with concurrent chemo-radiation and high dose chemotherapy. Annals of Oncology 2002; 13(Suppl. 2): 82 (abs. #279).
  • 82
    Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102(13): 42844289.
  • 83
    Di Venuti G, Nawgiri R, Foss F. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clin Lymphoma 2003; 4(3): 176178.
  • 84
    Karakas T, Bergmann L, Stutte HJ, et al. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk Lymphoma 1996; 24(1–2): 121129.
  • 85
    Bouabdallah R, Delmer A, Xerri L, Mounier N, Reyes F. ESHAP chemotherapy regimen and 13-cis-retinoic acid in elderly patients with untreated poor-prognosis peripheral T-cell lymphoma: a GELA phase II trial of feasability and efficacy. Annals of Oncology 2005; 16(Suppl. 5): v131 (abs. #322).
  • 86
    Delmer A, Mounier N, Gaulard P, et al. Intensified induction therapy with etoposide (VP16) and high-dose cytarabine (Ara-C) in patients aged less than 60 years with peripheral T-cell/NK lymphoma: Preliminary results of the phase II GELA study LNH98 T7. Proc Am Soc Clin Oncol 2003; 22: 591 (abs. #2375):
  • 87
    Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 2004; 100(2): 342349.
  • 88
    Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994; 12(12): 25882593.
  • 89
    Kurzrock R. Therapy of T-cell lymphomas with pentostatin. Ann N Y Acad Sci 2001; 941: 200205.
  • 90
    Monfardini S, Sorio R, Cavalli F, et al. Pentostatin (2′-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group. Oncology 1996; 53(2): 163168.
  • 91
    Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001; 113(1): 185187.
  • 92
    Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104(11): 24372441.
  • 93
    Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000; 18(13): 26032606.
  • 94
    Czuczman M, Porcu P, Johnson J, Niedzwiecki D, Canellos G, Cheson B. CALGB 59901:Results of a Phase II Study of 506U78 in CTCL and PTCL. Blood 2004; 104: (abs. #2486) 682a.
  • 95
    Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 8292082924.
  • 96
    Weidmann E, Hess G, Krause S, et al. Combination chemoimmunotherapy using Alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (campath-FCD) is an effective first-line regimen in peripheral T-cell lymphomas. Blood 2004; 104: abstract 2640.
  • 97
    Dang N. Advances in targeted therapeutics for T-cell lymphomas. Monogr Lymphoma 2005; 6(1): 610.
  • 98
    d'Amore F, Relander T, Hagberg H, et al. HuMax-CD4 (zanolimumab), a fully human monoclonal antibody: early results of an ongoing clinical trial in CD4+ peripheral T-cell lymphoma of non-cutaneous typ. Blood 2005; 106: (abs. #3354) 937a.
  • 99
    Hagberg H, Pettersson M, Bjerner T, Enblad G. Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Med Oncol 2005; 22: 21912194.
  • 100
    Forero-Torres A, Bernstein S, Gopal A, et al. SGN-30 (Anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma. Blood 2004; 104: (abs. #2637) 721a722a.
  • 101
    Ansell S, Byrd J, Horwitz S, et al. Phase I/II, open-label, dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma. Blood 2004; 104: (abs. #2636) 721a.
  • 102
    Nakase K, Kita K, Nasu K, et al. Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol 1994; 46(3): 179183.
  • 103
    Talpur R, Jones DM, Alencar AJ, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126(3): 575583.
  • 104
    Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19(2): 376388.
  • 105
    Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007; 136(3): 439447.
  • 106
    Duvic M. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. Clin Lymphoma 2000; 1 (Suppl. 1): S51S55.
  • 107
    Kreitman RJ, Pastan I. Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 2006; 7(10): 13011311.
  • 108
    Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007; 26(25): 36993703.
  • 109
    Zhao WL, Mourah S, Mounier N, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 2004; 84(11): 15121519.
  • 110
    Strupp C, Aivado M, Germing U, Gattermann N, Haas R. Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymphoma 2002; 43(1): 133137.
  • 111
    Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005; 19(11): 19931995.
  • 112
    Ganjoo KN, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47(6): 9981005.
  • 113
    E 2404 protocol summary (Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms), in http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=441194&version=Patient [Last accessed: October 26] 2006.
  • 114
    Zinzani PL, Tani M, Stefoni V, et al. Report of a phase II study of proteasome inhibitor Bortezomib (Velcade) in patients with relapsed or refractory T-cell lymphoma. Blood 2005; 106: (abs. #4764) 271b.
  • 115
    Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98(9): 28652868.
  • 116
    Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004; 103(12): 46364643.
  • 117
    Rodriguez J, Munsell M, Yazji S, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19(17): 37663770.
  • 118
    Zaja F, Russo D, Silvestri F, et al. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. Haematologica 1997; 82(2): 171177.
  • 119
    Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LN H87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15(3): 11311137.
  • 120
    Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003; 120(6): 978985.
  • 121
    Rodriguez J, Caballero MD, Gutierrez A, et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003; 88(12): 13721377.
  • 122
    Doocey RT, Toze CL, Connors JM, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005; 131(2): 223230.
  • 123
    Kahl C, Leithauser M, Wolff D, et al. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol 2002; 81(11): 646650.
  • 124
    Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22(11): 21722176.
  • 125
    Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37(5): 439449.
  • 126
    Armitage JO, Coiffier B. Activity of interferon-alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma. Ann Oncol 2000; 11(3): 359361.
  • 127
    Cooper DL, Braverman IM, Sarris AH, et al. Cyclosporine treatment of refractory T-cell lymphomas. Cancer 1993; 71(7): 23352341.
  • 128
    Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992; 80(3): 587592.
  • 129
    Kim K, Kim WS, Jung CW, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 2002; 38(1): 7581.
  • 130
    Prochazka V, Trneny M, Pytlik R, et al. Peripheral T-cell lymphoma, unspecified - the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007; 151(1): 103107.